XyloCor Therapeutics
Blood & Organ Banks · Pennsylvania, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
39 Addison Ln, Malvern, Pennsylvania, 19...Phone Number
(888) 290-0081Website
www.xylocor.comRevenue
<$5 MillionIndustry
About XyloCor Therapeutics
XyloCor Therapeutics specializes in gene therapy aimed at treating advanced coronary artery disease. The company is dedicated to enhancing the lives of patients by developing innovative therapies that address significant unmet clinical needs in cardiovascular disease. Currently, XyloCor is actively recruiting patients with chronic angina for its EXACT-2 clinical trial, which is being conducted across various sites in the US and UK. Their proprietary products are designed to provide novel solutions for individuals suffering from cardiovascular conditions.Explore more
XyloCor Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Compare Similar Companies to XyloCor Therapeutics
Compare insights from companies similar to XyloCor Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
XyloCor Therapeutics Tech Stack
A closer look at the technologies used by XyloCor Therapeutics
Top Blood & Organ Banks Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding XyloCor Therapeutics
Sign Up For FreeTo access detailed company insights
XyloCor Therapeutics specializes in gene therapy aimed at treating advanced coronary artery disease. The company is dedicated to enhancing the lives of patients by developing innovative therapies that address significant unmet clinical needs in cardiovascular disease. Currently, XyloCor is actively recruiting patients with chronic angina for its EX... Read More
